We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bedside Scanning Device to Enable Slide-Free Pathology for Complete Surgical Tumor Removal

By LabMedica International staff writers
Posted on 15 Aug 2024

Annually, millions are diagnosed with cancer, with surgical removal being the first treatment option for solid tumors. More...

However, distinguishing tumor margins from healthy tissue during surgery poses a challenge due to insufficient visual contrast. Current practices involve pathologists examining thin sections of tumors under microscopes to examine the borders between cancer and healthy tissue, but this method is time-consuming and only inspects a small portion of the tumor. Consequently, it can take several days or even weeks to confirm whether the entire tumor has been successfully removed. Researchers are now developing a sophisticated imaging system designed to instantly scan tumors during surgical procedures and ascertain within minutes if any cancerous tissue remains after the excision.

Researchers at Tulane University (New Orleans, LA, USA) are leading a project called MAGIC-SCAN (Machine-learning Assisted Gigantic Image Cancer margin SCANner) which aims to become one of the fastest high-resolution tissue scanners in the world. This system would be capable of identifying residual cancer cells on the surface of excised organs in a matter of minutes. The scanner would be trained on a vast database of clinical scans to accurately identify cancer cells at a cellular level, producing a detailed 3D map of the tumor’s surface. The new technology combines advances in microscopy, automation, computing, and machine learning, utilizing optical-sectioning super-resolution structured illumination microscopy to achieve twice the resolution of conventional microscopes.

This cutting-edge imaging tool promises to transform cancer surgery by enabling doctors, while the patient is still under anesthesia, to verify the complete removal of cancer, potentially eliminating the need for additional surgeries. The Tulane research team has been developing this technology with a focus on prostate and colorectal cancers—two of the most challenging tumors to excise—reducing detection time to approximately 45 minutes. They have built a prototype of this groundbreaking system and are now leading efforts to address the remaining technical, computing, and engineering challenges to actualize this device within five years. Efforts are underway to enhance imaging resolution quality and develop the necessary cyberinfrastructure to manage extensive data sets required for training the machine-learning models. Furthermore, the team plans to conduct clinical validation of the device and develop versions compliant with FDA regulations.

“Currently, it can take days to weeks before a surgeon knows whether all the tumor has been removed, and our goal is to get that down to 10 minutes, while the patient is still on the table,” said J. Quincy Brown, PhD, associate professor of biomedical engineering in the Tulane School of Science and Engineering and lead researcher on the project. “If successful, our work would transform cancer surgery as we know it.”

Related Links:
Tulane University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.